Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study

• Main Authors: Ploysyne Rattanakaemakorn (Author), Parawee Chevaisrakul (Author), Chanisada Wongpraparut (Author), Praveena Chiowchanwisawakit (Author), Napatra Tovanabutra (Author), Pimchanok Tantiwong (Author), Warayuwadee Amornpinyo (Author), Panlop Chakkavittumrong (Author), Punchong Hanvivadhanakul (Author), Sumapa Chaiamnuay (Author), Supapat Laodheerasiri (Author), Bensachee Pattamadilok (Author), Charoen Choonhakarn (Author), Ajanee Mahakkanukrauh (Author), Duangkamol Aiewruengsurat (Author), Siripan Sangmala (Author), Nisa Pretikul (Author), Kittiwan Sumethkul (Author), Panchalee Satpanich (Author), Metavee Boonsiri (Author), Naruemon Sangob (Author), Pravit Asawanonda (Author), on behalf of PROMPT Study Group (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Secukinumab has proven to be effective and safe in psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in the phase 3 studies. However, data on real-world practice is limited. Methods This study is an ongoing, multicenter, 2-year observational study that...